Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.

Current oncology reports - 3 May 2021

Longley Jemma, Johnson Peter W M

Abstract excerpt

PURPOSE OF REVIEW: Epigenetic modifier gene mutations are common in patients with follicular lymphoma. Here we review the pathogenesis of these mutations and how they are targeted by epigenetic drugs including EZH2 inhibitors in both mutated and wild-type disease. RECENT FINDINGS: The use of EZH2 inhibitor tazematostat in early phase clinical trials has proved encouraging in the treatment of follicular lymphoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Histone Deacetylase Inhibitors

Share to Lymphoma, Follicular

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 33937922
DOI: 10.1007/s11912-021-01076-0
PMCID: PMC8088902

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.PMID 33937922Read ↗

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.Semantic proximity Read ↗

Treating lymphoma is now a bit EZ-er.Semantic proximity Read ↗

Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.Semantic proximity Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.Semantic proximity Read ↗

Epigenetic Dysregulation in Follicular LymphomaSemantic proximity Read ↗

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.Semantic proximity Read ↗

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.Semantic proximity Read ↗

EZH2 mutations are frequent and represent an early event in follicular lymphoma.Semantic proximity Read ↗

EZH2 alterations in follicular lymphoma: biological and clinical correlations.Semantic proximity Read ↗

Comparative Analysis of the Clinicopathological Features of Follicular Lymphoma With and Without EZH2 Y646 Mutation.Semantic proximity Read ↗

The follicular lymphoma epigenome regulates its microenvironment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.